<DOC>
	<DOCNO>NCT02985190</DOCNO>
	<brief_summary>This study phase II effcicacy tolerance azacitidine patient myelodysplatic syndrome steroid dependent resistent systemic auto-immune inflammatory disorder</brief_summary>
	<brief_title>A Study Azacitidine Myelodysplastic Syndrome ( MDS ) Associated Systemic Auto-immune Inflammatory Disorders</brief_title>
	<detailed_description>This trial prospective French nationwide study analyze effect treatment azacitidine patient MDS-associated SAID steroid dependence and/or resistance , correlation possible change immunological parameter</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form Age 18 year time signing informed consent form Must able adhere study visit schedule protocol requirement Diagnosis MDS use 2008 WHO classification myeloid neoplasm assess screen period IPSS intermediate 2 high , include AML 20 30 % marrow blast CMML WBC &lt; 13G/L marrow blast &gt; 10 % , IPSS low int 1 need treatment ( transfusion dependent anemia resistant ESAs and/or platelet 30 G/l 50 G/l bleed platelet transfusion requirement , and/or ANC &lt; 0.5 G/l infectious complication ) SAIDassociated MDS define accord usual international criterion SAID ( ie ACR criterion systemic lupus , Chapel Hill classification systemic vasculitis , etc… ) Steroid dependence and/or resistance SAID ( steroid dependence define impossibility decrease steroid least 2 month 15 mg/day ; steroid resistance response SAID least 1 mg/kg/day prednisone equivalent one month ) Ineligibility allogeneic stem cell transplantation follow 12 month No previous use lenalidomide No previous use hypomethylating agent Life expectancy ≥ 6 month Adequate liver function ( serum transaminase ≤ 3N ) Adequate renal function ( creatinine clearance MDRD formula &gt; 30 ml/min ) Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must : Have negative serum urine pregnancy test within 2 week prior begin treatment study . Lactating patient exclude . Agree use , able comply , effective contraception without interruption , 4 week start study drug throughout entire duration study drug therapy ( include dos interruption ) 3 month end study drug therapy . Male patient must : Agree need use condom engage sexual activity woman childbearing potential entire period treatment , even disruption treatment 3 month end treatment . Agree learn procedure preservation sperm start treatment . IPSS low intermediate1 Creatinine clearance MDRD formula &lt; 30 ml/min Serum total bilirubin , serum transaminase &gt; 3.0 x upper limit normal ( ULN ) ( except unconjugated hyperbilirubinemia due Gilbert 's disease secondary MDS ) Known hypersensitivity active substance excipients AZA History severe congestive heart failure , clinically unstable cardiac pulmonary disease Previous use lenalidomide Previous treatment hypomethylating agent Lifeexpectancy less six month another debilitate disease Uncontrolled invasive fungal infection time registration active serious infection control oral intravenous antibiotic Known positive HIV acute infectious hepatitis , type B C Any serious medical condition psychiatric illness prevent subject signing informed consent form place subject unacceptable risk he/she participate study . Active cancer prior history malignancy MDS ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease ≥ 3 year Pregnant lactate females No affiliation insurance system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Azacitidine</keyword>
	<keyword>MDS</keyword>
	<keyword>Systemic auto-immune inflammatory disorder</keyword>
</DOC>